Modified FGF-21 polypeptides and their uses
AssigneeAmbrx, Inc.
InventorsThomas P. Cujec, Roberto Mariani, Anna-Maria A. Hays Putnam, William M. Keefe, Nick Knudsen, Lillian Ho, Jason Pinkstaff, Vadim Kraynov
Life of this patent
Estimating the term…
Abstract
Modified FGF-21 polypeptides and uses thereof are provided.
Claims52
A biologically active variant of FGF-21 comprising the amino acid sequence of SEQ ID NO:1 and comprising one or more non-naturally encoded amino acids wherein at least one of the one or more non-naturally encoded amino acids occurs at position 108 in the FGF-21 variant, and wherein the non-naturally encoded amino acid has the structure:
- and wherein the R group is any substituent other than one used in the twenty natural amino acids.
An FGF-21 variant encoded by a polynucleotide having a sequence shown in SEQ ID NO:
- 8, 9, 10, 11, 12, 13, or 14, wherein said polynucleotide comprises a selector codon, and wherein said variant comprises at least one non-naturally encoded amino acid substituted at a corresponding residue position 108 in SEQ ID NO:
- 1 or the corresponding amino acids of SEQ ID NOs:
- 2-7, wherein the non-naturally occurring amino acid has the structure:
- and wherein the R group is any substituent other than one used in the twenty natural amino acids.
A FGF-21 variant comprising one or more amino acid substitution, addition or deletion wherein at least one of the one or more amino acid substitution, addition, or deletions occurs at amino acid position 108 of SEQ ID NO.:
- 1 that increases the expression of the FGF-21 variant in a recombinant host cell.
A biologically functional FGF-21 variant comprising a non-naturally encoded amino acid at position 108 of SEQ ID NO.:
- 1, and a linker, polymer or biologically active molecule that is attached to the non-naturally encoded amino acid wherein said non-naturally encoded amino acid is ribosomally incorporated into the polypeptide.
Dependencies are inferred from the claim text.